Phase 3Completed
Fimasartan/Amlodipine Combination Phase III
A Randomized, Double-blind Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Amlodipine Versus Fimasartan Monotherapy in Patients With Essential Hypertension Who Fail to Respond Adequately to Fimasartan Monotherapy.
- Sponsor
- Boryung Pharmaceutical Co., Ltd (Industry)
- Enrollment
- 143 enrolled
- Conditions
- Essential Hypertension
- Interventions
- Fimasartan and Amlodipine; Fimasartan
- Ages
- adults, older adults
- Registry
- NCT02152306
Full record on ClinicalTrials.gov
From the registry
The aim of this study is to ensure the superiority of Fimasartan/Amlodipine combination in hypotensive effect after 8 weeks of treatment over Fimasartan monotherapy in patients with hypertension who have no response to Fimasartan 60mg monotherapy.
Primary outcomes
- Change of Sitting Systolic Blood Pressure(SiSBP) at week 8 of Investigational Product(IP) Administration from the Baseline
History
Last registry update
Study completion
Primary completion
Registered
Started